Welcome to the Journal of Virus Eradication, a premier publication dedicated to advancing the field of virology and infectious disease research. Published by MEDISCRIPT LTD, this journal provides a vital platform for sharing cutting-edge research findings in key areas including epidemiology, immunology, and public health. With an impressive classification of Q2 in Epidemiology and Infectious Diseases for 2023, this journal exemplifies a commitment to high-quality scholarship and impactful research. The Journal of Virus Eradication is instrumental in disseminating knowledge that tackles viral threats, contributing to global health initiatives aimed at virus containment and eradication. Researchers, professionals, and students alike will find this journal an invaluable resource, making significant contributions to the scientific community and society at large.

Advances in Virology, an esteemed journal published by HINDAWI LTD, serves as a pivotal platform for cutting-edge research in the field of virology and infectious diseases. With its ISSN 1687-8639 and E-ISSN 1687-8647, the journal has been a significant contributor to the scientific community since its initiation as an Open Access resource in 2009, allowing researchers from around the globe to access groundbreaking findings without barriers. Operating out of the United States and recognized for its commitment to high-quality research, the journal's relevance is underscored by its ranking in the Q3 category for Infectious Diseases and Q4 for Virology as of 2023. The time frame of publications spans from 2009 to 2024, reflecting a continuous commitment to exploring the evolving landscape of virology. This journal not only promotes the dissemination of novel insights and methodologies but also fosters collaboration and innovation within the scientific community, making it an invaluable resource for researchers, professionals, and students alike.

Virology Journal, published by BMC, stands as a prominent open-access platform since 2004, dedicated to advancing the field of virology and infectious diseases. With its E-ISSN: 1743-422X, this journal is based in the United Kingdom and strives to disseminate high-quality research that enhances our understanding of viral pathogens and their interactions with hosts. Recognized with a Q1 classification in the category of Infectious Diseases and a Q2 in Virology for 2023, Virology Journal holds significant standing in the academic community, ranking #82/344 in Medicine - Infectious Diseases and #26/80 in Immunology and Microbiology - Virology. Its commitment to open access ensures that cutting-edge research is freely available to researchers, professionals, and students worldwide, fostering collaboration and innovation in the fight against viral diseases. The journal aims to publish original research articles, reviews, and commentaries that will stimulate discourse and spark new ideas within the virology community.

Frontiers in Virology, published by FRONTIERS MEDIA SA, is an innovative open-access journal dedicated to advancing the understanding of viral biology, pathogenesis, surveillance, and control strategies. With the rapid evolution of viral threats, this journal serves as a critical platform for researchers, professionals, and students to disseminate and access high-quality research, reviews, and perspectives in virology. The journal places a strong emphasis on interdisciplinary approaches, promoting collaborative efforts that drive breakthroughs in the field. While the specific impact factor and H-index details are currently unavailable, Frontiers in Virology is committed to rigorous peer review and integrity in scientific publishing. Authors and readers will benefit from the extensive reach provided by open access, making groundbreaking insights available to a global audience, thus contributing significantly to the ongoing dialogue in virology and public health.

Virus Evolution is a premier open access journal published by Oxford University Press, dedicated to advancing the understanding of viral dynamics and evolutionary trends. Established in 2015, it has quickly ascended to a leading position in the fields of Microbiology and Virology, achieving a remarkable Q1 ranking in both categories for 2023. With its impactful research output, it ranks #27 out of 182 in Microbiology and #15 out of 80 in Virology, placing it in the top percentiles of the Scopus rankings. The journal serves as a vital resource for researchers, professionals, and students, providing a platform for the dissemination of innovative research that explores the genetic and ecological aspects of viruses. By embracing an open access model, Virus Evolution ensures that its high-quality content is accessible to a global audience, fostering collaboration and enhancing the impact of virology research worldwide.

REVIEWS IN MEDICAL VIROLOGY is a premier academic journal published by Wiley, dedicated to advancing the field of virology and infectious diseases. Established in 1991, this journal has gained a reputable standing, holding a Q1 ranking in both Infectious Diseases and Virology as of 2023, with impressive Scopus rankings placing it at #17 out of 344 in the realm of Medicine - Infectious Diseases, and #8 out of 80 in Immunology and Microbiology - Virology. This reflects its substantial impact factor and contribution to ongoing research and scholarship. While it is not an Open Access publication, REVIEWS IN MEDICAL VIROLOGY offers vital insights and comprehensive reviews that cater to a diverse audience including researchers, healthcare professionals, and students pursuing knowledge in medical virology. The journal serves as a vital resource for understanding the complexities of viral pathogens and the evolving landscape of antiviral therapeutics, making it an essential read for those poised at the forefront of infectious disease research.

The Journal of Clinical Virology Plus, published by Elsevier, is an essential resource for researchers and professionals in the fields of virology and infectious diseases. Launched in 2021, this journal aims to bridge the gap between clinical research and application, fostering a deeper understanding of viral pathogenesis, diagnostics, and therapeutic strategies. With an ISSN of 2667-0380, this open-access journal brings cutting-edge findings to the global scientific community, facilitating the rapid dissemination of knowledge critical for advancing public health. Positioned in the Q3 category for both Infectious Diseases and Virology in 2023, its ranking reflects its growing influence and relevance in the academic landscape. The journal strives to support innovative research, collaborative studies, and comprehensive reviews that address contemporary challenges in clinical virology. As it converges through the years from 2021 to 2024, Journal of Clinical Virology Plus aims to be a central hub for vital discussions and breakthroughs in this dynamic field.

JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, published by TAYLOR & FRANCIS INC, serves as a pivotal platform for the dissemination of original research in the fields of biochemistry, molecular biology, and structural biology. With an ISSN of 0739-1102 and an E-ISSN of 1538-0254, this esteemed journal has garnered attention for its rigorous peer-review process and commitment to high-quality scientific inquiry since its inception in 1981. Ranking in the Q2 quartile for miscellaneous medicine and the Q3 quartile for both molecular and structural biology, it consistently demonstrates a significant impact within its specialties, evidenced by a high Scopus ranking. Researchers, professionals, and students are encouraged to engage with cutting-edge studies addressing the complex interactions and dynamics of biomolecules, making this journal a vital resource for advancing knowledge in the biological sciences. Although it does not offer open access options, its valuable contributions are vital for the ongoing discourse within the scientific community.

INTERVIROLOGY is a leading academic journal dedicated to advancing the field of virology and infectious diseases, published by KARGER. With a commendable history since its inception in 1973, the journal is currently poised to explore innovative virological research through to 2024. INTERVIROLOGY is indexed with the ISSN 0300-5526 and E-ISSN 1423-0100, reflecting its commitment to maintaining high scholarly standards. The journal is categorized within the Q3 quartile for both Infectious Diseases and Virology as of 2023, demonstrating its relevance and contribution to the academic community. With Scopus rankings placing it as #130 in Infectious Diseases and #41 in Virology, INTERVIROLOGY serves as an essential resource for researchers, professionals, and students seeking cutting-edge insights and discoveries in virology. While it currently operates under a subscription model, its rigorous peer-review process ensures a high quality of published content, making it a cornerstone for those dedicated to understanding and combating viral diseases.

Viral Immunology, published by Mary Ann Liebert, Inc, stands as a prominent journal dedicated to advancing the understanding of the interplay between viral infections and host immune responses. With a strong focus on immunology, molecular medicine, and virology, the journal provides a platform for the dissemination of high-quality research findings and innovative methodologies that could shape the future of these critical fields. Although it currently holds a Q3 rating across its relevant categories and a respectable ranking within the Scopus database, Viral Immunology continues to strive for excellence with a commitment to publishing influential research that informs both academic and clinical practices. The journal accepts submissions in various formats—original research, reviews, and commentaries—catering to a diverse readership that includes researchers, professionals, and students engaged in the biological and medical sciences. Readers can anticipate insightful articles that address urgent challenges in immunological responses to viral infections, paving the way for new therapeutic strategies and public health initiatives.